Skip to content

EU · EudraLex Vol.4

EU GMP Annex 1 2.5

2. Principle

Section text

The development of the CCS requires detailed technical and process knowledge. Potential sources of contamination are attributable to microbial and cellular debris (e.g. pyrogen, endotoxin) as well as particulate (e.g. glass and other visible and sub-visible particles). Elements to be considered within a CCS should include (but are not limited to):

i. Design of both the plant and processes including the associated documentation.

ii. Premises and equipment.

iii. Personnel.

iv. Utilities.

v. Raw material controls – including in-process controls.

vi. Product containers and closures.

vii. Vendor approval – such as key component suppliers, sterilisation of components and single use systems (SUS), and critical service providers.

viii. Management of outsourced activities and availability/transfer of critical information between parties, e.g. contract sterilisation services.

ix. Process risk management.

x. Process validation.

xi. Validation of sterilisation processes.

xii. Preventative maintenance – maintaining equipment, utilities and premises (planned and unplanned maintenance) to a standard that will ensure there is no additional risk of contamination.

xiii. Cleaning and disinfection.

xiv. Monitoring systems - including an assessment of the feasibility of the introduction of scientifically sound, alternative methods that optimize the detection of environmental contamination.

xv. Prevention mechanisms – trend analysis, detailed investigation, root cause determination, corrective and preventive actions (CAPA) and the need for comprehensive investigational tools.

xvi. Continuous improvement based on information derived from the above.

Source: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · retrieved 2026-11-15

Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.